HC Wainwright Forecasts Strong Price Appreciation for Biora Therapeutics (NASDAQ:BIOR) Stock

Biora Therapeutics (NASDAQ:BIOR) had its price target boosted by stock analysts at HC Wainwright from $15.00 to $23.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Biora Therapeutics Stock Performance

BIOR opened at $1.63 on Monday. The company has a fifty day moving average price of $4.64 and a two-hundred day moving average price of $6.00. The firm has a market capitalization of $7.37 million, a PE ratio of -0.13 and a beta of 1.27. Biora Therapeutics has a 52 week low of $1.55 and a 52 week high of $19.90.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.